Ixazomib citrate (MLN 9708; Ninlaro)

Description: MLN9708 (also known as ixazomib citrate; MLN-9708; trade name Ninlaro) is a prodrug of Ixazomib (MMLN-2238) which is an orally bioavailable and 2nd generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN9708 is hydrolyzed to the biologically active form, MLN2238, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (beta5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, it is less potent to beta1 and little activity to beta2. MLN9708 exhibits excellent antitumor activity in both solid tumor and hematologic preclinical xenograft models.

References: Cancer Res. 2010 Mar 1; 70(5):1970-80; Clin Cancer Res. 2011 Aug 15; 17(16):5311-21.

Related CAS #: 1239908-20-3 (citrate) 1201902-80-8 1072833-77-2 (free)

Synonym: MLN9708; MLN-9708; MLN 9708; ixazomib citrate; MMLN-2238-prodrug; MMLN 2238-prodrug; MMLN2238-prodrug; Ixazomib-prodrug; Ninlaro.

Chemical Name: 4-(carboxymethyl)-2-((R)-1-(2-(2, 5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1, 3, 2-dioxaborinane-4-carboxylic acid

InChi Key: YTXSYWAKVMZICI-PVCZSOGJSA-N

InChi Code: InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-17(29)8-20(34-21, 19(31)32)7-16(27)28)25-15(26)9-24-18(30)12-6-11(22)3-4-13(12)23/h3-4, 6, 10, 14H, 5, 7-9H2, 1-2H3, (H, 24, 30)(H, 25, 26)(H, 27, 28)(H, 31, 32)/t14-, 20?/m0/s1

SMILES Code: O=C(C(C1)(CC(O)=O)OB([CH](NC(CNC(C2=CC(Cl)=CC=C2Cl)=O)=O)CC(C)C)OC1=O)O